Cipla500087Pharmaceuticals
Cipla's Q2 results were largely in line with estimates, with a dip in profit and muted US sales due to supply issues
By ScoutQuest · · 1 min read
- Revenue
- 7,400 crore rupees
- Revenue estimate
- 7,498 crore rupees
- Margins
- 18.7 percent
- Margin estimate
- 18.3 percent
- India growth
- 12 percent
Heard on business television between 15:47:19 - 15:50:19 IST.
- Revenue came in at around 7,400 crore rupees versus street estimate of 7,498 crore rupees.
- Margins came in at around 18.7% versus estimate of 18.3%.
- Profit was lower than street expectations.
- India business grew around 12 percent, at the upper end of expected 10-12% range.
- US business hit by supply issues of key drug Lanreotide, came in at $170 million versus estimate of $172 million.
- Other markets (emerging markets, Europe) were flat YoY; API and other segment fell sharply.
- Pankaj Pandey said India growth of 12% is lower than peers doing mid-to-high numbers, and US growth was muted, so nothing exciting, not surprised by the stock reaction.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Cipla
Cipla reported modest Q2 numbers but maintained its US revenue and EBITDA margin guidance, prompting mixed brokerage reactions
28 Oct 2026
Cipla posts audio recording of Q2/H1 FY27 earnings conference call on its website
27 Oct 2026
Cipla reported mixed Q2 results with revenue largely in line but profitability under pressure
27 Oct 2026
Source: Live TV News Channel · 27 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.